Table 1.
Sociodemographic Characteristics of the HIV Outbreak Cohort Compared With HIV Uninfected PWID in Glasgow
| HIV Outbreak Cohort (n = 156) | HIV Uninfected PWID (n = 780) | P Value | ||
|---|---|---|---|---|
| Social Characteristics | Sex | |||
| Female | 53/156 (34%) | 186/780 (24%) | ||
| Male | 103/156 (66%) | 590/780 (76%) | ||
| Unknown | 0/156 (0%) | 4/780 (1%) | ||
| <.05 | ||||
| Age | ||||
| <35 | 39/156 (25%) | 111/780 (14%) | ||
| 35–39 | 49/156 (31%) | 196/780 (25%) | ||
| 40–44 | 31/156 (20%) | 217/780 (28%) | ||
| 45+ | 37/156 (24%) | 256/780 (33%) | ||
| <.01 | ||||
| Homelessness (defined as no tenancy) | ||||
| Yes | 100/156 (64%) | 198/780 (25%) | ||
| No | 56/156 (36%) | 576/780 (74%) | ||
| Unknown | 0/156 (0%) | 6/780 (1%) | ||
| <.0001 | ||||
| In the 6 Months Before HIV Diagnosis | ||||
| Incarceration | Not available | |||
| Yes | 54/156 (35%) | |||
| No | 102/156 (65%) | |||
| Risk Behaviors | Injecting Drug Use | |||
| Yes | 130/156 (81%) | 523/780 (67%) | ||
| No | 26/156 (19%) | 251/780 (32%) | ||
| Unknown | 0/156 (0%) | 6/780 (1%) | ||
| <.0001 | ||||
| Main Drug Injected | ||||
| Cocaine | 18/130 (14%) | 114/523 (22%) | ||
| Heroin | 51/130 (39%) | 366/523 (70%) | ||
| Heroin and cocaine | 61/130 (47%) | 15/523 (3%) | ||
| Other | 0/130 (0%) | 28/523 (5%) | ||
| <.001 | ||||
| Self-Reported Sharing of Needles or Syringes | ||||
| Yes | 62/130 (48%) | 52/523 (10%) | ||
| No | 26/130 (20%) | 465/523 (89%) | ||
| Unknown | 42/130 (32%) | 6/523 (1%) | ||
| <.0001 | ||||
| Sexual Intercourse | Not available | |||
| Yes | 93/156 (60%) | |||
| No | 55/156 (35%) | |||
| Unknown | 8/156 (5%) | |||
| Type of HIV Acquisition Risk Disclosed From Contact Tracing (Some Reported More Than 1 Type of Risk) | Not applicable | |||
| Injecting drug use/shared injecting equipment contacts | 97/156 (62%) | |||
| Sexual contacts | 72/156 (46%) | |||
| Sexual and sharing injecting equipment contacts | 40/156 (26%) | |||
| Harm Reduction | Prescribed opioid agonist therapy | |||
| Yes | 128/156 (82%) | 627/780 (80%) | ||
| No | 28/156 (18%) | 147/780 (19%) | ||
| Unknown | 0/156 (0%) | 6/780 (1%) | ||
| .823 | ||||
| Acute Presentations | Glasgow acute hospital unscheduled presentations | Not available | ||
| None | 54/156 (34%) | |||
| 1–5 | 87/156 (56%) | |||
| 6–10 | 12/156 (8%) | |||
| >10 | 3/156 (2%) | |||
| BBV Status | HIV infection duration (recent infection defined as IgG avidity <40%) | Not applicable | ||
| Early | 53/156 (34%) | |||
| Chronic | 101/156 (65%) | |||
| Unknown | 2/156 (1%) | |||
| HCV status at diagnosis | ||||
| Ab positive, HCV PCR/Ag negative | 58/156 (37) | 190/780 (24) | ||
| Ongoing/active HCV infection | 92/156 (59) | 268/780 (34) | ||
| HCV negative (Ab and Ag/PCR) | 6/156 (4) | 262/780 (34) | ||
| Unknown | 0/156 (0%) | 60/780 (8) | ||
| <.001 |
Abbreviations: Ab, antibody; Ag, antigen; BBV, blood-borne virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IgG, immunoglobulin G; PCR, polymerase chain reaction; PWID, people who inject drugs.